ENDRA Life Sciences (NDRA)
(Delayed Data from NSDQ)
$5.19 USD
+0.06 (1.17%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $5.17 -0.02 (-0.39%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NDRA 5.19 +0.06(1.17%)
Will NDRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NDRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NDRA
What Makes ENDRA Life Sciences (NDRA) a New Strong Buy Stock
NDRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NDRA
NDRA Sees Lucid Capital Markets as Sole Manager for Recent Offering | NDRA Stock News
Endra Life Sciences files to sell 15.7M shares of common stock
Gold Falls 1%; ProKidney Shares Spike Higher
12 Health Care Stocks Moving In Tuesday's Intraday Session
US Stocks Mixed; Small Business Sentiment Falls In June